Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 821-826

  Lü, Xinquan ^a   Deng, Qing ^a   Li, Huixiang ^a   Suo, Zhenhe ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 fluorouracil; Anti apoptosis; Breast cancer; Drug resistance; Stem cell

Indexed keywords

BETA CATENIN; BREAKPOINT CLUSTER REGION PROTEIN; CD24 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; SURVIVIN; TRANSCRIPTION FACTOR SOX2;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CLONOGENESIS; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

EID: 79960269096     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.279     Document Type: Article

References (38)

1. Eramo A, Ricci-Vitiani L, Zeuner A, et al: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241, 2006.
2. Phillips TM, McBride WH and Pajonk F: The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785, 2006.
3. Tanei T, Morimoto K, Shimazu K, et al: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15: 4234-4241, 2009.
4. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
5. Mimeault M, Hauke R, Mehta PP and Batra SK: Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11: 981-1011, 2007.
6. Reguart N, He B, Taron M, You L, Jablons DM and Rosell R: The role of Wnt signaling in cancer and stem cells. Future Oncol 1: 787-797, 2005.
7. Mishra L, Shetty K, Tang Y, Stuart A and Byers SW: The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 24: 5775-5789, 2005.
8. He B, Barg RN, You L, et al: Wnt signaling in stem cells and non-small-cell lung cancer. Clin Lung Cancer 7: 54-60, 2005.
9. Kruger JA, Kaplan CD, Luo Y, et al: Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108: 3906-3912, 2006.
10. Scholer HR, Dressler GR, Balling R, Rohdewohld H and Gruss P: Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J 9: 2185-2195, 1990.
11. Scholer HR, Ruppert S, Suzuki N, Chowdhury K and Gruss P: New type of POU domain in germ line-specific protein Oct-4. Nature 344: 435-439, 1990.
12. Odorico JS, Kaufman DS and Thomson JA: Multilineage differentiation from human embryonic stem cell lines. Stem Cells 19: 193-204, 2001.
13. Hubner K, Fuhrmann G, Christenson LK, et al: Derivation of oocytes from mouse embryonic stem cells. Science 300: 1251-1256, 2003.
14. Chew JL, Loh YH, Zhang W, et al: Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 25: 6031-6046, 2005.
15. Park IH, Zhao R, West JA, et al: Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146, 2008.
16. Maruyama M, Ichisaka T, Nakagawa M and Yamanaka S: Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. J Biol Chem 280: 24371-24379, 2005.
17. Masui S, Nakatake Y, Toyooka Y, et al: Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635, 2007.
18. Ginis I, Luo Y, Miura T, et al: Differences between human and mouse embryonic stem cells. Dev Biol 269: 360-380, 2004.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
20. Ponti D, Costa A, Zaffaroni N, et al: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511, 2005.
21. Balic M, Lin H, Young L, et al: Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12: 5615-5621, 2006.
22. + tumor cells in invasive breast carcinomas. Hum Pathol 39: 1096-1102, 2008.
23. + cells with cancer stem cell characteristics. Breast Cancer Res 10: R10, 2008.
24. Stride BD, Valdimarsson G, Gerlach JH, Wilson GM, Cole SP and Deeley RG: Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 49: 962-971, 1996.
25. D'Hondt V, Caruso M and Bank A: Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents. Hum Gene Ther 8: 1745-1751, 1997.
26. Lautier D, Canitrot Y, Deeley RG and Cole SP: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
27. Abaan OD, Mutlu PK, Baran Y, Atalay C and Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest 27: 201-205, 2009.
28. Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9, 2009.
29. Chuthapisith S, Eremin J, El-Sheemey M and Eremin O: Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol 19: 27-32, 2010.
30. Dave B and Chang J: Treatment resistance in stem cells and breast cancer. J Mammary Gland Biol Neoplasia 14: 79-82, 2009.
31. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V and Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339, 1998.
32. Doyle LA, Yang W, Abruzzo LV, et al: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
33. Ross DD, Yang W, Abruzzo LV, et al: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429-433, 1999.
34. Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5: 67, 2006.
35. Khan S, Aspe JR, Asumen MG, et al: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 100: 1073-1086, 2009.
36. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998.
37. Wang J, Guo LP, Chen LZ, Zeng YX and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007.
38. Kornblau SM, Qiu YH, Bekele BN, et al: Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected 'survivor cells'. Cell Cycle 5: 2769-2777, 2006.